Natural Compound Derived from Pomegranates Boosts Heart Function by 80 Percent in Experimental Models of Stubborn Heart Failure

Researchers at King’s College London have published a landmark study revealing that urolithin A—a natural metabolite produced by the human body after the consumption of specific foods such as pomegranates, walnuts, and select berries—can drastically improve heart function. In experimental models of a notoriously difficult-to-treat form of heart failure, the compound enhanced overall cardiac performance by up to 80 percent. Published in the prestigious journal Science Advances and funded by the British Heart Foundation, the research opens a promising new avenue in cardiovascular medicine, targeting an unmet clinical need affecting millions of individuals worldwide.
Understanding Heart Failure with Preserved Ejection Fraction (HFpEF)
The findings carry profound implications for nearly half a million people in the United Kingdom, and millions more globally, who suffer from a specific diagnosis known as heart failure with preserved ejection fraction (HFpEF). Unlike traditional forms of heart failure where the heart muscle weakens and loses its pumping capacity, patients with HFpEF retain the heart’s ability to pump blood effectively. However, the condition causes the heart muscle to become dangerously stiff.
Because of this pathological rigidity, the heart struggles to relax properly between beats, severely impairing its ability to fill adequately with blood. This hemodynamic dysfunction triggers a cascade of debilitating symptoms, including chronic shortness of breath, persistent fatigue, a drastically reduced capacity for physical exercise, and an overall precipitous decline in the patient’s quality of life.
Accounting for roughly half of all diagnosed heart failure cases, HFpEF has long frustrated clinicians. The condition is notoriously difficult to manage due to its multifactorial etiology. It is frequently driven by a complex interplay of systemic issues associated with modern aging populations, including arterial hypertension, obesity, and type 2 diabetes. Because the heart continues to pump with normal force, conventional pharmacological treatments designed for systolic heart failure often prove ineffective. Consequently, clinical management has historically been restricted to treating underlying comorbidities, aggressive lifestyle modifications, weight loss management, and strict glycemic control.
The Biochemical Mechanism of Urolithin A
To combat this clinical challenge, researchers have increasingly turned their attention toward cellular health and mitochondrial function—the biochemical processes responsible for generating cellular energy. Urolithin A has previously garnered significant scientific interest for its associations with healthy aging, cellular cleanup, and longevity. However, its direct impact on myocardial mechanics had not been thoroughly explored until now.
In this groundbreaking study, the King’s College London research team discovered that urolithin A exerts a direct, protective influence on cardiac tissue by activating a vital regulatory protein known as PKGIα. This specific protein plays a critical physiological role in modulating vascular tone and facilitating the proper relaxation of heart muscle tissue. Specifically, urolithin A targets a precise amino acid residue within the protein, initiating a signaling pathway that yields profound cardiovascular benefits.
When tested in experimental animal models, treatment with urolithin A yielded remarkable results. Measures of overall heart function improved by as much as 80 percent compared to untreated control models. Furthermore, laboratory analyses demonstrated that the compound actively mitigated pathological remodeling. It promoted more effective tissue relaxation, curtailed myocardial fibrosis—the dangerous deposition of scar tissue that stiffens the heart—and successfully limited the abnormal enlargement of heart muscle cells, allowing them to retain more normal cellular architecture.
Validation in Engineered Human Heart Tissue
To bridge the critical gap between animal models and human clinical application, the research team subjected urolithin A to rigorous testing using cutting-edge engineered human heart tissue. Developed from human stem cells, this advanced laboratory model accurately replicates the complex three-dimensional structure, electrophysiology, and mechanical function of living human heart muscle.
The results mirrored the successes seen in the animal models. Urolithin A significantly enhanced tissue relaxation in the engineered human cardiac constructs, providing vital translational evidence that the cardioprotective benefits observed in the laboratory could successfully translate to human patients.
Crucially, unlike many experimental pharmaceutical compounds that face steep safety hurdles during early development phases, urolithin A boasts a distinct advantage. It has already undergone extensive human safety evaluations in separate nutritional and metabolic contexts, consistently demonstrating a highly favorable safety profile.
Expert Commentary and Official Reactions
The study has drawn praise and cautious optimism from leading cardiovascular researchers and public health officials.
Dr. Joseph Burgoyne, a senior author of the study and a prominent cardiovascular scientist at King’s College London, emphasized the urgency of finding new therapeutic targets for the condition. Dr. Burgoyne’s research centers on the molecular mechanisms governing vascular and cardiac health, particularly how cells respond to oxidative stress to regulate blood pressure and heart function.
"This type of heart failure is becoming increasingly common as populations age and rates of obesity and diabetes rise," Dr. Burgoyne stated. "Despite its growing burden, treatment options remain limited because the disease is complex and varies considerably between patients. Our findings identify a completely new therapeutic target and show that urolithin A can activate this pathway to improve heart relaxation and reduce disease severity. This raises the exciting possibility of developing new treatments that improve clinical outcomes and quality of life for people living with the condition."
Addressing public perception regarding diet, Dr. Burgoyne urged caution, noting that direct dietary consumption alone may not be sufficient for therapeutic intervention. "While there isn’t enough evidence to suggest that people should eat pomegranates to treat heart failure, these findings raise the possibility that dietary approaches that enhance urolithin A production may help alleviate this condition," he explained.
Professor James Leiper, Director of Research at the British Heart Foundation, echoed these sentiments while highlighting the need for continued, rigorous scientific validation through human clinical trials.
"Heart failure with preserved ejection fraction makes up roughly half of all heart failure cases in the UK, and can be debilitating," Professor Leiper remarked. "This early-stage study in experimental models suggests that urolithin A may help to improve the heart tissue’s ability to relax and fill with blood between beats, reducing the harmful changes to the heart muscle seen in HFpEF."
Professor Leiper emphasized that while the biological mechanisms are compelling, translating them to bedside medicine requires patience. "While these findings are promising, the benefits have so far been seen in animals and engineered human tissue, so clinical trials involving people are needed to test if this approach is effective for patients. In the meantime, a healthy, balanced diet remains one of the best ways to look after your heart. Eating plenty of fruit and vegetables is linked to better heart health, but it’s important to remember that no single food can prevent or treat heart disease on its own."
Future Implications and Clinical Outlook
The publication of this study in Science Advances marks an important milestone in translational cardiology. By identifying PKGIα as a viable therapeutic target and demonstrating the efficacy of urolithin A in both animal and stem cell-derived human models, the King’s College London team has laid the groundwork for future clinical trials.
As cardiovascular researchers design subsequent phases of human testing, the medical community moves closer to addressing one of modern medicine’s most persistent challenges. While a dietary prescription for pomegranates remains premature for established heart failure patients, the targeted therapeutic development of urolithin A derivatives offers tangible hope for millions of individuals burdened by the daily constraints of HFpEF, potentially paving the way for a new generation of life-changing cardiovascular treatments.







